Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Aclaris Therapeutics

06/08/2026 13:29

Aclaris Therapeutics, Inc. ACRS.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -13 cents.  The mean expectation of ten analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -18 cents to -12 cents per share.
Revenue fell 8.3% to $1.63 million from a year ago; analysts expected $1.38 million. 
Aclaris Therapeutics, Inc.'s reported EPS for the quarter was a loss of 15 cents​.
The company reported a quarterly loss of $21.51 million.
Aclaris Therapeutics, Inc. shares had risen by 20.2% this quarter and gained 111.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 0.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $10.00, about 36.4% above its last closing price of $6.36
This summary was machine generated from LSEG data August 6 at 12:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.16
-0.15
Beat
Mar. 31 2026 
-0.16
-0.15
Beat
Dec. 31 2025 
-0.15
-0.16
Missed
Sep. 30 2025 
-0.13
-0.12
Beat